Human mesenchymal stem cells therapy improves cognitive function in a sporadic Alzheimer rat model

ZAPPA VILLAR MF; GARCÍA MG; MOREL GR; TRÍPODI LS; CRESPO R; REGGIANI PC

Buenos Aires

Congreso; 2nd Federation of Latin American and Caribbean Neuroscience Societies (FALAN) Congress; 2016

FALAN - IBRO

Alzheimer disease (AD), the most common form of dementia, is characterized by the degeneration of neurons and reduced brain glucose metabolism, as well as by the progressive decline of cognitive function. In this context, mesenchymal stem cell (MSC) therapy emerges as a promising therapeutic approach. We explored the therapeutic effect of intravenous administration of Human umbilical cord perivascular cells (HUCPVC) on cognitive performance and biochemical parameters in a rat model of sporadic AD induced by the intracerebroventricular injection of streptozotocin (STZ-icv).Young male rats were divided into 3 experimental groups (N=7-8/group): Intact, STZ and STZ+MSC. STZ and STZ+MSC received 3 mg/kg STZ-icv and, 24 days after, STZ+MSC received 4 times (every 18 days) HUCPVC (1x106 cells in 1 ml) in a tail vein. We performed different tests to estimate memory, depression- and anxiety-like behaviors. Our results showed that STZ treated rats were deficient in all behavioral tests (p